source
- UniQure submits experimental Huntington's gene therapy to FDA for accelerated reviewUniQure announced that it has filed its experimental gene therapy for Huntington's disease with the U.S. Food and Drug Administration, seeking accelerated approval. The submission follows earlier…
- Novartis’ BTK inhibitor remibrutinib cuts MS relapse rates in Phase 3, setting up FDA filingNovartis reported that its BTK inhibitor remibrutinib, already approved for chronic spontaneous urticaria, lowered annualized relapse rates in two Phase 3 studies of relapsing multiple sclerosis wh…